Project Grant R01CA316329
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $560K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
- The National Cancer Institute awarded Yale University $142,635 under the Cancer Research Manpower program (CFDA 93.398) on June 3, 2026, to support research decoding long noncoding RNA networks in lineage plasticity and androgen receptor-targeted therapy resistance in prostate cancer. The research employs genome-wide CRISPR interference screening targeting approximately 10,000 long noncoding RNAs to identify mechanisms driving resistance to androgen receptor-targeted therapies in metastatic...
- The National Cancer Institute awarded New York University School of Medicine $580,131 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the cellular properties and pathogenesis of double-null prostate cancer through genetically engineered mouse models and analysis of human castration-resistant prostate cancer data. The research examines how aberrant co-activation of HGF/MET and WNT/β-catenin signaling pathways induces prostate tumor growth and...
- The National Cancer Institute awarded Yale University $100,228 on January 31, 2027, under the Cancer Research Manpower program (CFDA 93.398) to fund research investigating the role of gigaxonin (GAN) in prostate cancer therapy resistance. The project supports basic research identifying GAN as a modifier of response to androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer. The work employs CRISPR-mediated knockout and transcriptomic analysis to characterize how...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded Yale University $488,162 on August 19, 2026, under the Cancer Biology Research program (CFDA 93.396) to catalog disease processes over the lifespan of glioma using the International Glioma Longitudinal Analysis (GLASS) Consortium dataset. The award funds analysis of tumor heterogeneity and its evolution in response to treatment across the GLASS database, which since 2014 has...
- The National Cancer Institute awarded Yale University $610,637 in project grant funding on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer and optimize drug delivery platforms for locoregional treatment of advanced melanoma. Yale will develop bioadhesive and non-adhesive biodegradable nanoparticles engineered to deliver cytotoxic and immune conditioning agents selectively to tumor cells, the tumor microenvironment, and tumor-draining lymph nodes. The research...
- The National Cancer Institute (within the Department of Health and Human Services National Institutes of Health) awarded Yale University $615,287 under the Cancer Biology Research program (CFDA 93.396) on July 10, 2026, to investigate aberrant glycosylation pathways as a therapeutic target in non-small cell lung cancer with KRAS/LKB1 co-mutations. The research focuses on the ALG5 gene's oncogenic role in the N-glycosylation biosynthesis pathway and its contribution to aggressive lung...
- The National Cancer Institute awarded Weill Medical College of Cornell University $169,291 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the cooperative role of E2F1 and interacting proteins in driving advanced prostate cancer. The project investigates the molecular mechanisms underlying neuroendocrine prostate cancer (NEPC), an aggressive androgen receptor-independent transformation of prostate adenocarcinoma that develops resistance to...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded University of Wisconsin–Madison $634,791 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) for development of shark antibody radiopharmaceuticals (SHARPs) targeting lineage plasticity in castration-resistant prostate cancer. The funded work develops bispecific antibody constructs that engage two antigens simultaneously to overcome treatment...
- The National Cancer Institute awarded Yale University $226,884 under the Cancer Research Manpower program (CFDA 93.398) on January 16, 2026, to support research training in cancer science. The award funds investigation into the role of aberrant m5C mRNA modification in translation initiation and cancer, with the recipient conducting screening of approximately 35,000 human endogenous 5′-untranslated region sequences from multiple tissues to identify m5C installation targets by NSUN2 and NSUN6...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Yale University $696,189 on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms of CD8 T cell differentiation in tumor-draining lymph nodes. The research examines how CD8 T cells—specifically progenitor-exhausted (TPEX) cells housed in tumor-draining lymph nodes associated with lung adenocarcinoma—maintain stemlike properties and...